Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coya Therapeutics (COYA) EBT (2022 - 2025)

Coya Therapeutics (COYA) has disclosed EBT for 4 consecutive years, with $12.1 million as the latest value for Q4 2025.

  • Quarterly EBT rose 21.98% to $12.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$3.8 million through Dec 2025, down 50.64% year-over-year, with the annual reading at -$21.2 million for FY2025, 35.89% down from the prior year.
  • EBT hit $12.1 million in Q4 2025 for Coya Therapeutics, up from -$2.4 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $12.1 million in Q4 2025 to a low of -$7.3 million in Q1 2025.
  • Historically, EBT has averaged -$1.5 million across 4 years, with a median of -$2.9 million in 2023.
  • Biggest five-year swings in EBT: surged 445.03% in 2024 and later tumbled 110.78% in 2025.
  • Year by year, EBT stood at -$2.0 million in 2022, then surged by 190.6% to $1.8 million in 2023, then soared by 445.03% to $9.9 million in 2024, then grew by 21.98% to $12.1 million in 2025.
  • Business Quant data shows EBT for COYA at $12.1 million in Q4 2025, -$2.4 million in Q3 2025, and -$6.1 million in Q2 2025.